Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.36 |
| ▸ | IGF2R | P11717 | 2/20 | 0.36 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21080960 | 0.91 | LGALS3 (0.43) | MAPK1LGALS3LGALS8CA1CA2 | |
| SCHEMBL21080958 | 0.88 | MAPK1 (0.44) | MAPK1LGALS3LGALS8SLC2A1CA1 | |
| SCHEMBL21080969 | 0.88 | LGALS3 (0.35) | MAPK1LGALS3LGALS8CA1CA2 | |
| SCHEMBL21080974 | 0.86 | MAPK1 (0.51) | MAPK1LGALS3LGALS8SLC2A1LGALS4 | |
| SCHEMBL25484566 | 0.84 | GAA (0.48) | MAPK1LGALS3LGALS8LGALS4 | |
| SCHEMBL17297124 | 0.84 | GAA (0.48) | MAPK1LGALS3LGALS8LGALS4 | |
| SCHEMBL17339700 | 0.84 | GAA (0.48) | MAPK1LGALS3LGALS8LGALS4 | |
| SCHEMBL30232030 | 0.84 | GAA (0.48) | MAPK1LGALS3LGALS8LGALS4 | |
| SCHEMBL24531345 | 0.84 | GAA (0.48) | MAPK1LGALS3LGALS8LGALS4 | |
| SCHEMBL18769744 | 0.84 | GAA (0.48) | MAPK1LGALS3LGALS8LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336966-B2 | Fragrance compositions and uses thereof | THE PROCTER & GAMBLE COMPANY (US) | 2019-07-02 | — | — | US | claimed |
| US-20210393506-A1 | FRAGRANCE BLENDS AND METHODS FOR PREPARATION THEREOF | JPMORGAN CHASE BANK, N.A. | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336966-B2 | Fragrance compositions and uses thereof | CUTA, DPM1, PLIN5 | MAPK1 4405/4885LGALS3 3147/4885LGALS8 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.